Third-generation P2Y12 inhibitors, prasugrel and ticagrelor, are recommended based on improved clinical outcomes and more potent platelet inhibition compared with clopidogrel in acute coronary syndrome (ACS) [34]. The gene discussed is P2RY12; the disease is acute coronary syndrome.